Compare Nike Inc (NKE) vs TransMedics Group Inc (TMDX) Price & Performance

Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.

Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.

TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.

The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.